RxDoctor Payments Data

Tanya Nikolova, MD

Hospice and Palliative Medicine · Marietta, GANPI 1477589620

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 33.4% of the total. Reporting peaked in 2023 at $351 and has fallen 69.0% since, to $109 in 2025.

$1,253in general payments, 2019–2025

Across 68 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$418
  • Pfizer$182
  • Inari Medical, Inc.$102
  • Novartis$96
  • Xeris Pharmaceuticals, Inc.$93
  • UCB, Inc.$58
  • plus $303 from 10 others

What the payments were for

  • Food & beverage$1,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,253 in reported general payments places this provider in the 85th percentile of 69 hospice and palliative medicine providers in Georgia.

See all hospice and palliative medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$104,987
Medicare patients
357
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$9,139
Metoprolol Succinate13$161
Pantoprazole Sodium20$161
Oxycodone Hcl15$110
Atorvastatin Calcium13$37
Amlodipine Besylate12$30
Furosemide11$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$182$9,13916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 69 hospice and palliative medicine providers in Georgia.

Other hospice and palliative medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →